Welcome to: Rimonabant Information Source (what is rimonabant)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

NEW ORLEANS, November 9 / PRNewswire / - - Results From Rio-North America Trial Show That First Year Improvements in cardiovascular risk factors in the second year of treatment Popular In T Make Job Transfers: good reasons to terminate Your Job Awaken Your Audience: How to grab attention in Public Speaking Time Management Tip: You must Track The Hand-offs Strategic Management tasks for the Small Business Owner market on the basis of the government through innovation: How public sector leaders are improving collaboration and focusing on citizens The results of a two-year Phase III study in 3040 patients with rimonabant (Acomplia (TM)), the first in a new class of therapeutic agents called selective CB1 blockers, demonstrate that the benefits achieved with rimonabant 20mg at the end of the first year of the study were sustained in the second year of therapy with good safety and tolerability profile vs.placebo.

Rimonabant Pricelist

Please wait while we load the price list
Pounds-off prescription Blockbuster obesity drug aims to win $ 4BN sales for Sanofi-Aventis obesity drug to generate a splash. " (Sanofi-Aventis) Long-term benefits of rimonabant in two-year study. The FDA panel of experts concluded that su? Dale thoughts turned out to be a side effect of taking Acomplia that is ... Read the full article with a free trial version MyWire ..

rimonabant was also associated with significantly greater improvements in cardio-metabolic measures, compared with placebo. Serum levels of adiponectin increased by an average of 1. 6 mg / ml in the treated group, compared with a 0. 2-mcg/mL decline in the placebo patients and. Insulin resistance levels (known as HOMA-IR levels) increased by an average of 0. 33 units in the placebo group and decreased by an average of 1. 89 units in the rimonabant arm. The average HDL-cholesterol increased by 10% on rimonabant vs.by 3% on placebo, while the average formulas triglyceride levels decreased by 16% on the drug, compared to 4% on placebo. The most common adverse events associated with rimonabant were dizziness (11%), nausea (9%), upper respiratory tract infection (7%), anxiety (6%), and depressed mood (6%).